22 January 2018
News and Views
Links and Services
A study in the latest issue of the New England Journal of Medicine compares cisplatin with cisplatin plus doxorubicin for standard-risk hepatoblastoma.
Preoperative cisplatin alone may be as effective as cisplatin plus doxorubicin in standard-risk h
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors